CareDx Preliminary Q4 Revenue Up 25%

CareDx reported preliminary Q4 revenue of approximately $108 million, up 25% year-over-year, with testing services revenue of about $78 million (+23%) and testing services volume of ~53,000 (+17%). The company provided preliminary 2025 revenue of roughly $380 million, up 14% YoY, with testing services revenue of ~$274 million (+10%) and testing services volume of ~200,000 (+14%). The results and guidance point to continued demand and healthy top-line growth in CareDx's testing business, suggesting positive operational momentum for the transplant diagnostics company.

Analysis

Market structure: CareDx (CDNA) shows healthy top-line momentum — Q4 revenue ~$108M (+25% YoY) and preliminary 2025 revenue ~$380M (+14%) — driven ~72% by testing services, with Q4 volume +17% but testing revenue +23% implying ~6% price/mix benefit; conversely 2025 guidance shows testing revenue +10% versus volume +14% (≈4% price/mix headwind). Winners include CDNA (recurring transplant-testing franchise) and labs with scale; losers could be smaller transplant-test entrants facing price pressure and payers if volumes slow. Competitive dynamics: volume-led growth with mixed pricing suggests CDNA has temporary pricing power but faces margin risk as volume growth outpaces revenue growth next year, opening room for competitive pricing and reimbursement pressure.

Risk assessment: Tail risks include adverse CMS reimbursement changes (3–10% rate cuts), FDA/CLIA regulatory actions, or a material lab-capacity outage; a single regulatory shock could cut EBITDA by >15% in 12 months. Short-term (days-weeks): stock sensitive to confirmatory earnings and forward guidance revisions; medium (3–6 months): pricing/reimbursement clarity and transplant volume data; long-term (1–3 years): durable share gains if CDNA sustains 10–15% volumes annually and stabilizes price/mix. Hidden dependencies: hospital transplant procedure trends, payer contract renewals, and test-mix shift to lower-priced panels could erode realized ASPs.

Trade implications: Establish a tactical 2–3% long in CDNA ahead of full results, scaling up only if guidance is raised >3% versus prelim or volumes accelerate >15% YoY; hedge with a 1–1.5% short in NTRA (Natera) as a relative-play expecting CDNA’s transplant focus to outperform NTRA’s mixed franchise. Options: buy a 3–6 month call spread (buy ATM, sell 20–25% OTM) to cap cost and target 20–30% upside; alternatively sell OTM puts (cash-secured) if willing to own below a 10% pullback. Rotate modest weight out of generic diagnostics (LabCorp/LH, Quest/ DGX) into higher-growth molecular diagnostics if data confirms pricing stability.

Contrarian angles: Consensus celebrates headline growth but underprices margin risk — 2025 preliminary figures flip to negative price/mix (~-4%) which could compress gross margins even as volumes rise; market may underreact to a small but persistent ASP decline. If CDNA can convert higher volumes into better payer contracts, upside is underappreciated; conversely, if CMS tweaks reimbursement, downside could be >25% from current levels. Historical parallel: molecular diagnostics names have re-rated sharply on reimbursement shifts (2018–2019); treat any positive guidance beat as a near-term catalyst but avoid full conviction until 2 sequential quarters show stabilizing ASPs.

Key Decisions for Investors

• Establish a 2–3% long position in CDNA ahead of full earnings release; add up to +2% more only if FY2025 revenue guidance is revised >3% above preliminary $380M or testing volumes accelerate >15% YoY in the next quarter.
• Implement a relative-value pair trade: go long CDNA (2%) and short NTRA (1–1.5%) to hedge market risk; unwind the short if NTRA reports better-than-expected transplant-related contract wins within 90 days.
• Use options to define risk: buy a 3–6 month call spread on CDNA (buy ATM, sell 20–25% OTM) sized to 1–1.5% of portfolio to target ~20–30% upside while capping premium; alternatively sell cash-secured puts 10% below current price if willing to own on a pullback.
• Risk-management triggers: trim or exit long exposure if testing revenue growth falls below +5% YoY or if company discloses a CMS/reimbursement headwind >5% anticipated impact to 2025 revenue within 30–60 days.